[go: up one dir, main page]

ES2152444T3 - Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos. - Google Patents

Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.

Info

Publication number
ES2152444T3
ES2152444T3 ES96104265T ES96104265T ES2152444T3 ES 2152444 T3 ES2152444 T3 ES 2152444T3 ES 96104265 T ES96104265 T ES 96104265T ES 96104265 T ES96104265 T ES 96104265T ES 2152444 T3 ES2152444 T3 ES 2152444T3
Authority
ES
Spain
Prior art keywords
group
sup
hydrogen
chain
short
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96104265T
Other languages
English (en)
Inventor
Harald Waldeck
Dagmar Holtje
Josef Messinger
Jochen Antel
Michael Wurl
Dirk Thormahlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2152444T3 publication Critical patent/ES2152444T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE ACCION INHIBITORIA DEL NEP DE FORMULA GENERAL I DONDE R{SUP,1} ES UN GRUPO ALCOXIALQUILO, AMBOS DE CADENA CORTA, EL RADICAL ALCOXI SUSTITUIDO POR UN GRUPO ALCOXI TAMBIEN DE CADENA CORTA, UN GRUPO FENILALQUILO (ESTE ULTIMO DE CADENA CORTA) O FENILOXIALQUILO (ESTE ULTIMO DE CADENA CORTA), LOS CUALES PUEDEN ESTAR OPCIONALMENTE SUSTITUIDOS EN EL ANILLO FENILICO CON ALQUILO, ALCOXI, LOS DOS DE CADENA CORTA, O HALOGENO, O UN GRUPO NAFTIL ALQUILO (ESTE ULTIMO DE CADENA CORTA), A ES CH{SUB,2} O O S, R{SUP,2} ES HIDROGENO O HALOGENO, R{SUP,3} ES HIDROGENO O HALOGENO, R{SUP,4} ES HIDROGENO O UN GRUPO QUE FORMA UN ESTER BIOLABIL, Y R{SUP,5} ES HIDROGENO O UN GRUPO QUE FORMA UN ESTER BIOLABIL, Y LAS SALES FISIOLOGICAMENTE ACEPTABLES DE LOS ACIDOS DE LA FORMULA I.
ES96104265T 1995-03-23 1996-03-18 Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos. Expired - Lifetime ES2152444T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19510566A DE19510566A1 (de) 1995-03-23 1995-03-23 Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
ES2152444T3 true ES2152444T3 (es) 2001-02-01

Family

ID=7757471

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96104265T Expired - Lifetime ES2152444T3 (es) 1995-03-23 1996-03-18 Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.

Country Status (25)

Country Link
US (1) US5677297A (es)
EP (1) EP0733642B1 (es)
JP (1) JP3942670B2 (es)
KR (1) KR100482499B1 (es)
CN (1) CN1059436C (es)
AR (1) AR023289A1 (es)
AT (1) ATE197801T1 (es)
AU (1) AU701271B2 (es)
CA (1) CA2172354C (es)
CZ (1) CZ289245B6 (es)
DE (2) DE19510566A1 (es)
DK (1) DK0733642T3 (es)
DZ (1) DZ2003A1 (es)
ES (1) ES2152444T3 (es)
GR (1) GR3035410T3 (es)
HU (1) HU226064B1 (es)
IL (1) IL117265A (es)
NO (1) NO305904B1 (es)
NZ (1) NZ286224A (es)
PL (1) PL184336B1 (es)
PT (1) PT733642E (es)
RU (1) RU2159768C2 (es)
SK (1) SK281079B6 (es)
UA (1) UA44712C2 (es)
ZA (1) ZA961243B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2781483A1 (fr) * 1998-07-21 2000-01-28 Hoechst Marion Roussel Inc Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant
DE19906310A1 (de) 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
MXPA03010341A (es) * 2001-05-18 2004-03-10 Solvay Pharm Gmbh Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos.
WO2003022853A1 (en) * 2001-09-10 2003-03-20 Tibotec Pharmaceuticals Ltd. Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol
KR100710547B1 (ko) * 2002-01-02 2007-04-24 에스케이 주식회사 (ｓ)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1Ｈ-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
AU2003206755B2 (en) 2002-01-16 2008-07-17 Solvay Pharmaceuticals B.V. Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US6842358B2 (en) * 2002-08-01 2005-01-11 Netlogic Microsystems, Inc. Content addressable memory with cascaded array
US7045653B2 (en) * 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
KR100710548B1 (ko) * 2002-12-26 2007-04-24 에스케이 주식회사 (ｓ)-3-아미노-2,3,4,5-테트라히드로-2-옥소-1Ｈ-1-벤자제핀-1-아세트산 및 이의 에스테르 화합물의 제조방법
TWI289141B (en) * 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
WO2005049035A1 (en) * 2003-11-18 2005-06-02 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
BRPI0506750A (pt) * 2004-01-12 2007-05-22 Solvay Pharm Bv uso de um composto
US7232813B2 (en) * 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
AU2005256634B2 (en) * 2004-06-23 2010-12-09 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
CN101119718B (zh) * 2005-02-18 2011-06-15 索尔瓦药物有限公司 包含nep-抑制剂，内源性内皮素产生系统抑制剂和利尿剂的药物组合物
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
EA201390335A1 (ru) 2010-09-01 2013-09-30 Арена Фармасьютикалз, Инк. Введение лоркасерина индивидуумам с почечной недостаточностью
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
CA2819153A1 (en) 2010-12-15 2012-06-21 Theravance, Inc. Neprilysin inhibitors
HRP20151115T1 (en) 2010-12-15 2015-11-20 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
KR101854874B1 (ko) 2011-02-17 2018-05-04 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제로서 치환된 아미노부티릭 유도체
US8449890B2 (en) 2011-02-17 2013-05-28 Theravance, Inc. Neprilysin inhibitors
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
EP2714660B1 (en) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
CN103596928B (zh) 2011-05-31 2017-02-15 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
ES2609810T3 (es) 2012-05-31 2017-04-24 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina donadores de óxido nítrico
CN104470521B (zh) 2012-06-08 2017-04-12 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
PT2864292T (pt) 2012-06-08 2017-07-10 Theravance Biopharma R&D Ip Llc Inibidores de neprisilina
KR102104954B1 (ko) 2012-08-08 2020-04-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
WO2014138053A1 (en) 2013-03-05 2014-09-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
AU2015210983B2 (en) 2014-01-30 2018-10-04 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
CA2934898A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR102345318B1 (ko) 2014-12-02 2021-12-31 현대모비스 주식회사 에이밍 보정 구조를 구비한 차량용 램프
SG11201706308RA (en) 2015-02-11 2017-09-28 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
EP3259255B1 (en) 2015-02-19 2020-10-21 Theravance Biopharma R&D IP, LLC (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
CN105017154B (zh) * 2015-07-07 2017-10-10 浙江博聚新材料有限公司 一种3‑溴‑1,3,4,5‑四氢‑2h‑1‑苯并氮杂卓‑2‑酮制备方法
HUE055546T2 (hu) 2016-03-08 2021-12-28 Theravance Biopharma R&D Ip Llc Kristályos (2S,4R)-5-(5'-klór-2-fluor-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxi izoxazol-5-karboxamido)-2-metilpentánsav és alkalmazásaik
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
US20230118503A1 (en) * 2020-07-19 2023-04-20 Christopher Turski NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564612A (en) * 1983-04-22 1986-01-14 Takeda Chemical Industries, Ltd. Condensed, seven-membered ring compounds and their use
JPS608283A (ja) * 1983-06-29 1985-01-17 Mitsui Toatsu Chem Inc ベンゾチアゼピン誘導体およびその製造方法
WO1985004657A1 (en) * 1984-04-06 1985-10-24 Takeda Chemical Industries, Ltd. Fused 7-membered ring compounds and process for their preparation
IL72523A (en) * 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
IT1266570B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
IT1266571B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
JPH08269011A (ja) 1996-10-15
DE19510566A1 (de) 1996-09-26
PL184336B1 (pl) 2002-10-31
CA2172354A1 (en) 1996-09-24
CN1059436C (zh) 2000-12-13
EP0733642B1 (de) 2000-11-29
HUP9600680A3 (en) 1998-07-28
NZ286224A (en) 1997-09-22
GR3035410T3 (en) 2001-05-31
DK0733642T3 (da) 2001-01-15
IL117265A0 (en) 1996-06-18
PL313433A1 (en) 1996-09-30
US5677297A (en) 1997-10-14
KR960034178A (ko) 1996-10-22
ZA961243B (en) 1996-08-27
ATE197801T1 (de) 2000-12-15
SK35496A3 (en) 1997-02-05
SK281079B6 (sk) 2000-11-07
NO305904B1 (no) 1999-08-16
KR100482499B1 (ko) 2006-08-23
HU226064B1 (en) 2008-04-28
CN1147506A (zh) 1997-04-16
DZ2003A1 (fr) 2002-07-20
CZ86396A3 (en) 1996-10-16
UA44712C2 (uk) 2002-03-15
NO961181D0 (no) 1996-03-22
HUP9600680A2 (en) 1997-01-28
JP3942670B2 (ja) 2007-07-11
DE59606160D1 (de) 2001-01-04
EP0733642A1 (de) 1996-09-25
AU4821096A (en) 1996-10-03
CZ289245B6 (cs) 2001-12-12
NO961181L (no) 1996-09-24
PT733642E (pt) 2001-03-30
IL117265A (en) 2000-07-16
CA2172354C (en) 2002-10-08
AU701271B2 (en) 1999-01-21
RU2159768C2 (ru) 2000-11-27
HU9600680D0 (en) 1996-05-28
AR023289A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
ES2152444T3 (es) Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2060951T3 (es) Azaindenos.
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
ES8601994A1 (es) Un procedimiento para la preparacion de pirazolo-y piridazo-pirazolinas,-piridazinas y-diazepinas.
ES2186961T3 (es) Derivados de acido benzazepinona-n-acetico sustituidos por acido fosfonico, asi como procedimiento para su preparacion y medicamentos que contienen estos compuestos.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
ES8402290A1 (es) Procedimiento para la preparacion de nuevos 6,11-dihidrodibenzo (b,e)-tiepin-11-n-alcohilnorescopin-eteres cuaternarios.
ES8306373A1 (es) "procedimiento para la preparacion de 9-(2-(3-indolil)-etil)-1-oxa-4,9-diazaspiro (5.5) undecan-3-onas".
ES8603382A1 (es) Derivados fenolicos
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
ES8604545A1 (es) Procedimiento para preparar nuevos derivados de acidos feni-laceticos
ES2045180T3 (es) Nuevo procedimiento para la obtencion de 4-aciloxi-3-hidroxietil-azetidinonas.
ES2082057T3 (es) Esteres del acido acrilico pirimidil-substituidos.
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2147629T3 (es) Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene.
ES2111930T3 (es) Antagonistas del acido amp y procedimientos de tratamiento con la ayuda de estos.
ES2052761T3 (es) Nuevos esteres del acido androstano 17-carboxilico, procedimiento para su preparacion y medicamento que los contiene.
ES2045189T3 (es) Nuevos agentes anti-arritmicos i.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2133686T3 (es) Nuevos derivados de benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2098570T3 (es) Amidas de un acido 4-amino-2-ureido-pirimidina-5-carboxilico, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
ES2027057T3 (es) Procedimiento para preparar 2-aza-4-(alcoxicarbonil)espiro(4,5)decan-3-onas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 733642

Country of ref document: ES